Study on 2-Arylthio-5-Iodo Pyrimidine Derivatives as Novel Nonnucleoside Inhibitors Against Hepatitis B Virus DNA Replication

References

• Lavanchy D . Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepatitis11 (2), 97–107 (2004).
   PubMed Web of Science ®Google Scholar
• Alaluf MB , ShlomaiA. New therapies for chronic hepatitis B. Liver Int. doi:10.1111/liv.13086 (2016) ( Epub ahead of print).
   Google Scholar
• Poland GA . Evaluating existing recommendations for hepatitis A and B vaccination. Am. J. Med.118 (Suppl. 10A), S16–S20 (2005).
   PubMedGoogle Scholar
• Bhattacharya D , ThioCL. Review of hepatitis B therapeutics. Clin. Infect. Dis.51 (10), 1201–1208 (2010).
   PubMed Web of Science ®Google Scholar
• Perrillo R . Benefits and risks of interferon therapy for hepatitis B. Hepatology49 (5 Suppl.), S103–S111 (2009).
   PubMed Web of Science ®Google Scholar
• Michailidis E , KirbyKA, HachiyaAet al. Antiviral therapies: focus on hepatitis B reverse transcriptase. Int. J. Biochem. Cell Biol.44 (7), 1060–1071 (2012).
   PubMed Web of Science ®Google Scholar
• Jia H , RaiD, ZhanP, ChenX, JiangX, LiuX. Recent advance of the hepatitis B virus inhibitors: an overview. Future Med. Chem.7 (5), 587–607 (2015).
   PubMed Web of Science ®Google Scholar
• Morikawa K , SudaG, SakamotoN. Viral life cycle of hepatitis B virus: host factors and druggable targets. Hepatol. Res. doi:10.1111/hepr.12650 (2016) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Lin C-L , YangH-C, KaoJ-H. Hepatitis B virus: new therapeutic perspectives. Liver Int.36, 85–92 (2016).
   PubMed Web of Science ®Google Scholar
• Wang Y-J , YangL, ZuoJ-P. Recent developments in antivirals against hepatitis B virus. Virus Res.213, 205–213 (2016).
   PubMed Web of Science ®Google Scholar
• Liu N , ZhaoF, JiaHet al. Non-nucleoside anti-HBV agents: advances in structural optimization and mechanism of action investigations. Med. Chem. Comm.6 (4), 521–535 (2015).
   Google Scholar
• Peng Z , XuemeiJ, XinyongL. Naturally occurring and synthetic bioactive molecules as novel non-nucleoside HBV inhibitors. Mini-Rev. Med. Chem.10 (2), 162–171 (2010).
   PubMed Web of Science ®Google Scholar
• Petersen J , DandriM, MierWet al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol.26 (3), 335–341 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang J , FuL-L, TianMet al. Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]–APOA1–HBx–Beclin1-mediated autophagic pathway in HBV therapy. Biorg. Med. Chem.23 (5), 976–984 (2015).
   PubMed Web of Science ®Google Scholar
• Cai D , MillsC, YuWet al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob. Agents Chemother.56 (8), 4277–4288 (2012).
   PubMed Web of Science ®Google Scholar
• Chen Y , ChengG, MahatoRI. RNAi for treating hepatitis B viral infection. Pharm. Res.25 (1), 72–86 (2008).
   PubMed Web of Science ®Google Scholar
• Yeo H , LiY, FuLet al. Synthesis and Antiviral Activity of Helioxanthin Analogues. J. Med. Chem.48 (2), 534–546 (2005).
   PubMed Web of Science ®Google Scholar
• Wakui Y , InoueJ, UenoYet al. Inhibitory effect on hepatitis B virus in vitro by a peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone. Biochem. Biophys. Res. Commun.396 (2), 508–514 (2010).
   PubMed Web of Science ®Google Scholar
• Deres K , SchroderCH, PaessensAet al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science299 (5608), 893–896 (2003).
   PubMed Web of Science ®Google Scholar
• Stray SJ , BourneCR, PunnaS, LewisWG, FinnMG, ZlotnickA. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc. Natl Acad. Sci. USA102 (23), 8138–8143 (2005).
   PubMed Web of Science ®Google Scholar
• Perni RB , ConwaySC, LadnerSK, ZaifertK, OttoMJ, KingRW. Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication. Bioorg. Med. Chem. Lett.10 (23), 2687–2690 (2000).
   PubMed Web of Science ®Google Scholar
• Katen SP , ChirapuSR, FinnMG, ZlotnickA. Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem. Biol.5 (12), 1125–1136 (2010).
   PubMed Web of Science ®Google Scholar
• Na L , FabaoZ, PengZ, XinyongL. Review of small synthetic molecules targeting HBV capsid assembly. Med. Chem.11 (8), 710–716 (2015).
   PubMed Web of Science ®Google Scholar
• Yang L , ShiL-P, ChenH-Jet al. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacol. Sin.35 (3), 410–418 (2014).
   PubMed Web of Science ®Google Scholar
• Wang Y-J , LuD, XuY-Bet al. A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation. Antimicrob. Agents Chemother.59 (11), 7061–7072 (2015).
   PubMed Web of Science ®Google Scholar
• Jones SA , HuJ. Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention. Emerg. Microbes Infect.2 (9), e56 (2013).
   PubMedGoogle Scholar
• Yang Q , KangJ, ZhengLet al. Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. J. Med. Chem.58 (9), 3693–3703 (2015).
   PubMed Web of Science ®Google Scholar
• Mehta A , LuX, BlockTM, BlumbergBS, DwekRA. Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc. Natl Acad. Sci. USA94 (5), 1822–1827 (1997).
   PubMed Web of Science ®Google Scholar
• Lazar C , DurantelD, MacoveiAet al. Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res.76 (1), 30–37 (2007).
   PubMed Web of Science ®Google Scholar
• Bondada L , DetorioM, BassitLet al. Adenosine dioxolane nucleoside phosphoramidates as antiviral agents for human immunodeficiency and hepatitis B viruses. ACS Med. Chem. Lett.4 (8), 747–751 (2013).
   PubMed Web of Science ®Google Scholar
• Nakamura A , TamuraN, YasutakeY. Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of hepatitis B virus polymerase. Acta Crystallogr. F Struct. Biol. Commun.71 (11), 1384–1390 (2015).
   PubMedGoogle Scholar
• Lee J , ShimH, ParkYet al. 2,5-Pyridinedicarboxylic acid derivatives as non-nucleosidic reverse transcriptase inhibitors of hepatitis B virus. Bioorg. Med. Chem. Lett.12 (19), 2715–2717 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang L , TangX, CaoYet al. Synthesis and biological evaluation of novel 2-arylalkylthio-5-iodine-6-substituted-benzyl-pyrimidine-4(3H)-ones as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Molecules19 (6), 7104–7121 (2014).
   PubMed Web of Science ®Google Scholar
• Qin H , LiuC, GuoYet al. Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem.18 (9), 3231–3237 (2010).
   PubMed Web of Science ®Google Scholar
• Donleavy JJ . The utilization of S-benzyl thiuronium chloride for the isolation and identification of organic acids. J. Am. Chem. Soc.58 (6), 1004–1005 (1936).
   Google Scholar
• Finlay MR , ButtarD, CritchlowSEet al. Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor. Bioorg. Med. Chem. Lett.22 (12), 4163–4168 (2012).
   PubMed Web of Science ®Google Scholar
• Lucifora J , ZoulimF. The life cycle of hepatitis B virus and antiviral targets. Future Virol.6 (5), 599–614 (2011).
   Web of Science ®Google Scholar
• Lamontagne J , MillsC, MaoRet al. Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system. Antiviral Res.98 (1), 19–26 (2013).
   PubMed Web of Science ®Google Scholar
• Stuyver LJ , LostiaS, AdamsMet al. Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. Antimicrob. Agents Chemother.46 (12), 3854–3860 (2002).
   PubMed Web of Science ®Google Scholar
• Ladner SK , OttoMJ, BarkerCSet al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother.41 (8), 1715–1720 (1997).
   PubMed Web of Science ®Google Scholar
• Xu YB , YangL, WangGFet al. Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion. Antiviral Res.1076–15 (2014).
   PubMed Web of Science ®Google Scholar
• Feld JJ , ColledgeD, SozziV, EdwardsR, LittlejohnM, LocarniniSA. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res.76 (2), 168–177 (2007).
   PubMed Web of Science ®Google Scholar
• Pan Y , WangY, BryantSH. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors. J. Chem. Inf. Model.53 (4), 938–947 (2013).
   PubMed Web of Science ®Google Scholar